Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 22 of 47

Summary of Benefits: Atypical Antipsychotics for Major Depressive Disorder

Atypical antipsychotics increase the rate of response or remission when used to augment SSRIs and SNRIs. The strength of evidence for risperidone is moderate.

In monotherapy, quetiapine XR improves remission and response rates when compared with placebo, but olanzapine does not show efficacy. The strength of evidence in support of these findings is moderate.